BioSpace News Archive

Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary anti-PSMA antibody-drug conjugate (ADC) investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.

Synaptogenix, Inc. today announced that it entered into an agreement with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS).

Redwood Scientific Technologies Inc. (RSCI. OTC. PK) announces a partnership with Silk Road Ent., Inc. (SKRJ, OTC, PK) for retail distribution of TBX FREE and TBX VAPE FREE, its smoking cessation products.

KayoThera, Inc. announces the strengthening of its financial resources through multiple grant awards and expansion of its previously announced Series A financing.

Agile Therapeutics, Inc.'s partnership with Afaxys Pharma is expected to play a key role in propelling the women’s healthcare company toward its $25-$30 million net annual revenue target for 2023.

SiPhox Health, the leader in building the next generation of lab-grade home health testing with silicon photonics, raised $27 million in funding including a $10M Seed financing and a $17M Series A round.

Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 23-27 in Anaheim, California.

Francis Medical, Inc. today announced the first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapor ablation therapy for managing prostate cancer.

Padagis, a leading provider of extended topical and other specialty pharmaceuticals, announced today the approval of its over-the-counter (OTC) labeling supplement for naloxone hydrochloride nasal spray (therapeutically equivalent to Narcan® nasal spray).

Rapid Medical™, a leading developer of advanced neurovascular devices, today announced new clinical data showing significant advantages of its novel COMANECI™ embolization assist device over established techniques to treat ruptured wide-neck intracranial aneurysms.